Sherene Loi

Sherene Loi

UNVERIFIED PROFILE

Are you Sherene Loi?   Register this Author

Register author
Sherene Loi

Sherene Loi

Publications by authors named "Sherene Loi"

Are you Sherene Loi?   Register this Author

100Publications

4851Reads

34Profile Views

Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series.

Asia Pac J Clin Oncol 2019 Dec 19;15(6):377-382. Epub 2019 Jul 19.

Division of Clinical Medicine and Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13195DOI Listing
December 2019

Metastatic Breast Cancer: TIL it's too late.

Clin Cancer Res 2019 Dec 2. Epub 2019 Dec 2.

Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-3490DOI Listing
December 2019

Around the world and back again.

Authors:
Sherene Loi

Nat Med 2019 Oct;25(10):1466

Peter MacCallum Cancer Centre, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-019-0578-0DOI Listing
October 2019

Persistent Impairment in Cardiopulmonary Fitness after Breast Cancer Chemotherapy.

Med Sci Sports Exerc 2019 08;51(8):1573-1581

Department of Sports Cardiology, Baker Heart and Diabetes Institute, Melbourne VIC, AUSTRALIA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1249/MSS.0000000000001970DOI Listing
August 2019

Triple-negative breast cancer: recent treatment advances.

F1000Res 2019 2;8. Epub 2019 Aug 2.

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12688/f1000research.18888.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681627PMC
August 2019

Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy.

Oncotarget 2019 Jul 23;10(45):4612-4614. Epub 2019 Jul 23.

Peter MacCallum Cancer Centre, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.27081DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659801PMC
July 2019

ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia.

Pathology 2019 Jun 7;51(4):345-348. Epub 2019 May 7.

Surgical Oncology, The University of Sydney, and Mater Hospital North Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2019.02.004DOI Listing
June 2019

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.

Front Immunol 2018 31;9:70. Epub 2018 Jan 31.

Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.00070DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797771PMC
February 2019

Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays.

PLoS One 2018 31;13(8):e0203346. Epub 2018 Aug 31.

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0203346PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118369PMC
February 2019

The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.

Breast Cancer Res Treat 2019 Feb 21;174(1):271-278. Epub 2018 Nov 21.

Cancer Care Centre, St George Hospital, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-5054-xDOI Listing
February 2019

Fine-tuning chemotherapy in the era of dual HER2 targeting.

Authors:
Sherene Loi

Lancet Oncol 2018 12 6;19(12):1551-1554. Epub 2018 Nov 6.

Peter MacCallum Cancer Centre, and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30661-2DOI Listing
December 2018

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.

N Engl J Med 2018 Nov 20;379(20):1926-1936. Epub 2018 Oct 20.

From the Institute of Cancer Research and Royal Marsden Hospital, London (N.C.T.); David Geffen School of Medicine at University of California, Los Angeles, Santa Monica (D.J.S.), and Pfizer Oncology, San Diego (X.H.) - both in California; National Cancer Center, Goyang-si, Gyeonggi-do (J.R.), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul (S.-A.I.) - both in South Korea; Dnipropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital 4, Dnipropetrovsk, Ukraine (I.B.); National Hospital Organization Osaka National Hospital, Osaka (N.M.), and Aichi Cancer Center Hospital, Nagoya (H.I.) - both in Japan; Istituto Europeo di Oncologia (M. Colleoni) and Pfizer Oncology (C.G.) - both in Milan; Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.), and Pfizer Oncology, Collegeville (C.H.B.) - both in Pennsylvania; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S. Loi); Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada (S.V.); Brustzentrum der Universität München, Munich (N.H.), and the German Breast Group, Neu-Isenburg (S. Loibl) - both in Germany; Institut Gustave Roussy, Villejuif, France (F.A.); Pfizer Oncology, Cambridge, MA (K.P.T.); and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago (M. Cristofanilli).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1810527
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1810527DOI Listing
November 2018

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

N Engl J Med 2018 11 20;379(22):2108-2121. Epub 2018 Oct 20.

From the Barts Cancer Institute, Queen Mary University of London, London (P.S.); Perlmutter Cancer Center, New York University School of Medicine, New York (S.A.); the Department of Medicine, University of California, San Francisco, San Francisco (H.S.R.), and Genentech, South San Francisco (L.M., S.Y.C., R.F.) - both in California; University Hospital Heidelberg, Heidelberg, Germany (A.S.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre (C.H.B.), and the University of São Paulo, São Paulo (R.H.) - both in Brazil; Aichi Cancer Center Hospital, Nagoya, Japan (H.I.); the Department of Medical Oncology, Institut Curie, Paris (V.D.); Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea (S.-A.I.); Florida Cancer Specialists and Research Institute, New Port Richey (G.S.W.); Roche, Basel, Switzerland (V.H., A.H.); Dana-Farber Cancer Institute, Boston (E.P.W.); Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S.L.); and the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore (L.A.E.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1809615
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1809615DOI Listing
November 2018

In the beginning, there was chaos: A perspective on the development of immuno-oncological biomarkers.

Semin Cancer Biol 2018 10 4;52(Pt 2):v-vi. Epub 2018 Aug 4.

Division of Research and Cancer Medicine, Peter Mac Callum Cancer Centre, University of Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2018.08.004DOI Listing
October 2018

Checkpoint blockade in the treatment of breast cancer: current status and future directions.

Br J Cancer 2018 07 29;119(1):4-11. Epub 2018 May 29.

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0126-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035268PMC
July 2018

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

J Clin Oncol 2018 04 22;36(10):981-990. Epub 2018 Feb 22.

Dimitrios Zardavas and Debora Fumagalli, Breast International Group; Christos Sotiriou, Université Libre de Bruxelles, Brussels, Belgium; Luc te Marvelde and Roger L. Milne, Cancer Council; Roger L. Milne and Sherene Loi, University of Melbourne, Melbourne; Barry Iacopetta, University of Western Australia, Western Australia; Sandra O'Toole and Elena Lopez-Knowles, Garvan Institute of Medical Research, Darlinghurst, Australia; George Fountzilas and Vassiliki Kotoula, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki; Evangelia Razis, Hygeia Hospital; George Papaxoinis, Hippokration Hospital, Athens, Greece; Heikki Joensuu, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Mary Ellen Moynahan, Memorial Sloan Kettering Cancer Center, New York, NY; Bryan T. Hennessy, Beaumont Hospital and Royal College of Surgeons, Dublin, Ireland; Ivan Bieche, Curie Institut, Paris; Thomas Bachelot, Centre de Recherche en Cancérologie de Lyon, Lyon; Stefan Michiels, Gustave Roussy and Inserm, Univ. Paris-Sud, Univ. Paris-Saclay, Villejuif, France; Lao H. Saal, Lund University, Lund; Olle Stal, Qing Wang, and Gizeh Perez-Tenorio, Linköping University, Linköping, Sweden; Jeanette Dupont Jensen, University of Southern Denmark, on behalf of the Danish Breast Cancer Cooperative Group, Odense, Denmark; Elena Lopez-Knowles, Royal Marsden NHS Trust and Institute of Cancer Research, London; Daniel W. Rea, University of Birmingham, Birmingham, United Kingdom; Mattia Barbaraeschi, Santa Chiara Hospital, Trento, Italy; Shinzaburo Noguchi, Osaka University, Osaka Japan; Hatem A. Azim Jr, American University of Beirut (AUB), Beirut, Lebanon; Enrique Lerma, Universitat Autònoma de Barcelona, Barcelona, Spain; Cornelis J.H. can de Velde, Leiden University Medical Center, Leiden, the Netherlands; Vicky Sabine, University of Guelph, Guelph; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.8301DOI Listing
April 2018

Investigating the role of tumor-infiltrating lymphocytes in advanced HER2-positive breast cancer.

Chin Clin Oncol 2018 02 14;7(1). Epub 2017 Nov 14.

Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2017.10.06DOI Listing
February 2018

Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance.

Lancet Oncol 2018 01 7;19(1):3-5. Epub 2017 Dec 7.

Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30905-1DOI Listing
January 2018

Novel Targeted Agents and Immunotherapy in Breast Cancer.

Am Soc Clin Oncol Educ Book 2017 ;37:65-75

From the Vanderbilt University Medical Center, Nashville, TN; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, Singapore, Singapore; Peter MacCallum Cancer Centre, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_175631DOI Listing
December 2017

Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice.

Biochim Biophys Acta Rev Cancer 2017 Dec 20;1868(2):527-537. Epub 2017 Oct 20.

Ramon y Cajal University Hospital, Ctra. Colmenar Viejo km. 9, 100, 28034 Madrid, Spain; Baselga Institute of Oncology, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbcan.2017.10.003DOI Listing
December 2017

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:
Shona Hendry Roberto Salgado Thomas Gevaert Prudence A Russell Tom John Bibhusal Thapa Michael Christie Koen van de Vijver M V Estrada Paula I Gonzalez-Ericsson Melinda Sanders Benjamin Solomon Cinzia Solinas Gert G G M Van den Eynden Yves Allory Matthias Preusser Johannes Hainfellner Giancarlo Pruneri Andrea Vingiani Sandra Demaria Fraser Symmans Paolo Nuciforo Laura Comerma E A Thompson Sunil Lakhani Seong-Rim Kim Stuart Schnitt Cecile Colpaert Christos Sotiriou Stefan J Scherer Michail Ignatiadis Sunil Badve Robert H Pierce Giuseppe Viale Nicolas Sirtaine Frederique Penault-Llorca Tomohagu Sugie Susan Fineberg Soonmyung Paik Ashok Srinivasan Andrea Richardson Yihong Wang Ewa Chmielik Jane Brock Douglas B Johnson Justin Balko Stephan Wienert Veerle Bossuyt Stefan Michiels Nils Ternes Nicole Burchardi Stephen J Luen Peter Savas Frederick Klauschen Peter H Watson Brad H Nelson Carmen Criscitiello Sandra O'Toole Denis Larsimont Roland de Wind Giuseppe Curigliano Fabrice André Magali Lacroix-Triki Mark van de Vijver Federico Rojo Giuseppe Floris Shahinaz Bedri Joseph Sparano David Rimm Torsten Nielsen Zuzana Kos Stephen Hewitt Baljit Singh Gelareh Farshid Sibylle Loibl Kimberly H Allison Nadine Tung Sylvia Adams Karen Willard-Gallo Hugo M Horlings Leena Gandhi Andre Moreira Fred Hirsch Maria V Dieci Maria Urbanowicz Iva Brcic Konstanty Korski Fabien Gaire Hartmut Koeppen Amy Lo Jennifer Giltnane Marlon C Rebelatto Keith E Steele Jiping Zha Kenneth Emancipator Jonathan W Juco Carsten Denkert Jorge Reis-Filho Sherene Loi Stephen B Fox

Adv Anat Pathol 2017 Nov;24(6):311-335

Departments of *Pathology §§§Medical Oncology, Peter MacCallum Cancer Centre, Melbourne †The Sir Peter MacCallum Department of Oncology Departments of **Pathology ∥∥Medicine, University of Melbourne ¶¶Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville #Department of Anatomical Pathology, St Vincent's Hospital Melbourne, Fitzroy ††Department of Medical Oncology, Austin Health ‡‡Olivia Newton-John Cancer Research Institute, Heidelberg §§School of Cancer Medicine, La Trobe University, Bundoora §§§§§Centre for Clinical Research and School of Medicine, The University of Queensland ∥∥∥∥∥Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane §§§§§§§§§§The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst ∥∥∥∥∥∥∥∥∥∥Australian Clinical Labs, Bella Vista ‡‡‡‡‡‡‡‡‡‡‡‡Directorate of Surgical Pathology, SA Pathology §§§§§§§§§§§§Discipline of Medicine, Adelaide University, Adelaide, Australia ***********Department of Surgical Oncology, Netherlands Cancer Institute †††††††††††††Department of Pathology ##Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands ###Université Paris-Est ****INSERM, UMR 955 ††††Département de pathologie, APHP, Hôpital Henri-Mondor, Créteil ∥∥∥∥∥∥∥∥∥Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay ¶¶¶¶¶¶¶¶¶¶INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif ##########Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre †††††††Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre ‡‡‡‡‡‡‡University of Auvergne UMR1240, Clermont-Ferrand, France ‡‡‡‡Department of Medicine, Clinical Division of Oncology §§§§Institute of Neurology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna ††††††††††††††Institute of Pathology, Medical University of Graz, Austria ∥∥∥∥European Institute of Oncology ¶¶¶¶School of Medicine ######Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan ¶¶¶¶¶¶¶¶¶¶¶¶¶Department of Surgery, Oncology and Gastroenterology, University of Padova #############Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy †††††Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona †††††††††††Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain §Department of Pathology and TCRU, GZA ¶¶¶Department of Pathology, GZA Ziekenhuizen, Antwerp ∥Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven ‡‡‡‡‡‡‡‡‡‡‡Department of Pathology, University Hospital Leuven, Leuven, Belgium ¶Department of Pathology, AZ Klina, Brasschaat ††††††Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus, Wilrijk ∥∥∥Molecular Immunology Unit ‡‡‡‡‡‡Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles ‡Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet **************European Organisation for Research and Treatment of Cancer (EORTC) Headquarters *******Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium §§§§§§§Department of Surgery, Kansai Medical School, Hirakata, Japan #######Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, South Korea ∥∥∥∥∥∥∥∥Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center ¶¶¶¶¶¶¶¶Institute of Oncology, Gliwice Branch, Gliwice, Poland ‡‡‡‡‡‡‡‡‡‡‡‡‡‡Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg †††††††††Institute of Pathology, Charité Universitätsmedizin Berlin ‡‡‡‡‡‡‡‡‡VMscope GmbH, Berlin ¶¶¶¶¶¶¶¶¶German Breast Group GmbH, Neu-Isenburg, Germany **********Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency ††††††††††Department of Biochemistry and Microbiology, University of Victoria, Victoria Departments of ‡‡‡‡‡‡‡‡‡‡Medical Genetics #########Pathology and Laboratory Medicine ¶¶¶¶¶¶¶¶¶¶¶Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC ###########Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada §§§§§§§§§§§Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Doha, Qatar ‡‡‡‡‡‡‡‡Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center §§§§§§§§Warren Alpert Medical School of Brown University, Providence ¶¶¶¶¶National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA †††Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Departments of ‡‡‡Pathology, Microbiology and Immunology ########Department of Medicine, Vanderbilt University Medical Centre *********Vanderbilt Ingram Cancer Center, Nashville §§§§§§§§§Department of Pathology, Yale University School of Medicine, New Haven ∥∥∥∥∥∥∥∥∥∥∥Department of Oncology, Montefiore Medical Centre, Albert Einstein College of Medicine ∥∥∥∥∥∥∥Montefiore Medical Center ¶¶¶¶¶¶¶The Albert Einstein College of Medicine, Bronx, NY ********Department of Pathology, Brigham and Women's Hospital #####Cancer Research Institute and Department of Pathology, Beth Israel Deaconess Cancer Center ******Harvard Medical School ¶¶¶¶¶¶¶¶¶¶¶¶Division of Hematology-Oncology, Beth Israel Deaconess Medical Center ††††††††Department of Cancer Biology ‡‡‡‡‡‡‡‡‡‡‡‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO ‡‡‡‡‡Department of Cancer Biology, Mayo Clinic, Jacksonville, FL ∥∥∥∥∥∥Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN ¶¶¶¶¶¶Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA ††††††††††††Department of Pathology, New York University Langone Medical Centre ############New York University Medical School *************Perlmutter Cancer Center §§§§§§§§§§§§§Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University ***************Department of Pathology, Memorial Sloan-Kettering Cancer Center ####Departments of Radiation Oncology and Pathology, Weill Cornell Medicine, New York, NY *****Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX ∥∥∥∥∥∥∥∥∥∥∥∥Pathology Department, Stanford University Medical Centre, Stanford ∥∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Pathology, Stanford University, Palo Alto ***Department of Pathology, School of Medicine, University of California, San Diego §§§§§§§§§§§§§§Research Pathology, Genentech Inc., South San Francisco, CA *************Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda ¶¶¶¶¶¶¶¶¶¶¶¶¶¶Translational Sciences, MedImmune, Gaithersberg, MD §§§§§§Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover ##############Translational Medicine, Merck & Co. Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638696PMC
November 2017

Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.

Cancer Immunol Res 2017 10 28;5(10):871-884. Epub 2017 Aug 28.

Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-17-0150DOI Listing
October 2017

CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.

Cancer Res 2017 10 30;77(20):5652-5663. Epub 2017 Aug 30.

Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-17-0707DOI Listing
October 2017

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Authors:
Shona Hendry Roberto Salgado Thomas Gevaert Prudence A Russell Tom John Bibhusal Thapa Michael Christie Koen van de Vijver M V Estrada Paula I Gonzalez-Ericsson Melinda Sanders Benjamin Solomon Cinzia Solinas Gert G G M Van den Eynden Yves Allory Matthias Preusser Johannes Hainfellner Giancarlo Pruneri Andrea Vingiani Sandra Demaria Fraser Symmans Paolo Nuciforo Laura Comerma E A Thompson Sunil Lakhani Seong-Rim Kim Stuart Schnitt Cecile Colpaert Christos Sotiriou Stefan J Scherer Michail Ignatiadis Sunil Badve Robert H Pierce Giuseppe Viale Nicolas Sirtaine Frederique Penault-Llorca Tomohagu Sugie Susan Fineberg Soonmyung Paik Ashok Srinivasan Andrea Richardson Yihong Wang Ewa Chmielik Jane Brock Douglas B Johnson Justin Balko Stephan Wienert Veerle Bossuyt Stefan Michiels Nils Ternes Nicole Burchardi Stephen J Luen Peter Savas Frederick Klauschen Peter H Watson Brad H Nelson Carmen Criscitiello Sandra O'Toole Denis Larsimont Roland de Wind Giuseppe Curigliano Fabrice André Magali Lacroix-Triki Mark van de Vijver Federico Rojo Giuseppe Floris Shahinaz Bedri Joseph Sparano David Rimm Torsten Nielsen Zuzana Kos Stephen Hewitt Baljit Singh Gelareh Farshid Sibylle Loibl Kimberly H Allison Nadine Tung Sylvia Adams Karen Willard-Gallo Hugo M Horlings Leena Gandhi Andre Moreira Fred Hirsch Maria V Dieci Maria Urbanowicz Iva Brcic Konstanty Korski Fabien Gaire Hartmut Koeppen Amy Lo Jennifer Giltnane Marlon C Rebelatto Keith E Steele Jiping Zha Kenneth Emancipator Jonathan W Juco Carsten Denkert Jorge Reis-Filho Sherene Loi Stephen B Fox

Adv Anat Pathol 2017 Sep;24(5):235-251

Departments of *Pathology §§§Medical Oncology, Peter MacCallum Cancer Centre, Melbourne †The Sir Peter MacCallum Department of Oncology Departments of **Pathology ∥∥Medicine, University of Melbourne ¶¶Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville #Department of Anatomical Pathology, St Vincent's Hospital Melbourne, Fitzroy ††Department of Medical Oncology, Austin Health ‡‡Olivia Newton-John Cancer Research Institute, Heidelberg §§School of Cancer Medicine, La Trobe University, Bundoora §§§§§Centre for Clinical Research and School of Medicine, The University of Queensland ∥∥∥∥∥Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane §§§§§§§§§§The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst ∥∥∥∥∥∥∥∥∥∥Australian Clinical Labs, Bella Vista ‡‡‡‡‡‡‡‡‡‡‡‡Directorate of Surgical Pathology, SA Pathology §§§§§§§§§§§§Discipline of Medicine, Adelaide University, Adelaide, Australia ***********Department of Surgical Oncology, Netherlands Cancer Institute †††††††††††††Department of Pathology ##Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands ###Université Paris-Est ****INSERM, UMR 955 ††††Département de pathologie, APHP, Hôpital Henri-Mondor, Créteil ∥∥∥∥∥∥∥∥∥Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay ¶¶¶¶¶¶¶¶¶¶INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif ##########Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre †††††††Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre ‡‡‡‡‡‡‡University of Auvergne UMR1240, Clermont-Ferrand, France ‡‡‡‡Department of Medicine, Clinical Division of Oncology §§§§Institute of Neurology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna ††††††††††††††Institute of Pathology, Medical University of Graz, Austria ∥∥∥∥European Institute of Oncology ¶¶¶¶School of Medicine ######Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan ¶¶¶¶¶¶¶¶¶¶¶¶¶Department of Surgery, Oncology and Gastroenterology, University of Padova #############Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy †††††Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona †††††††††††Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain §Department of Pathology and TCRU, GZA ¶¶¶Department of Pathology, GZA Ziekenhuizen, Antwerp ∥Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven ‡‡‡‡‡‡‡‡‡‡‡Department of Pathology, University Hospital Leuven, Leuven, Belgium ¶Department of Pathology, AZ Klina, Brasschaat ††††††Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus, Wilrijk ∥∥∥Molecular Immunology Unit ‡‡‡‡‡‡Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles ‡Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet **************European Organisation for Research and Treatment of Cancer (EORTC) Headquarters *******Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium §§§§§§§Department of Surgery, Kansai Medical School, Hirakata, Japan #######Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, South Korea ∥∥∥∥∥∥∥∥Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center ¶¶¶¶¶¶¶¶Institute of Oncology, Gliwice Branch, Gliwice, Poland ‡‡‡‡‡‡‡‡‡‡‡‡‡‡Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg †††††††††Institute of Pathology, Charité Universitätsmedizin Berlin ‡‡‡‡‡‡‡‡‡VMscope GmbH, Berlin ¶¶¶¶¶¶¶¶¶German Breast Group GmbH, Neu-Isenburg, Germany **********Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency ††††††††††Department of Biochemistry and Microbiology, University of Victoria, Victoria Departments of ‡‡‡‡‡‡‡‡‡‡Medical Genetics #########Pathology and Laboratory Medicine ¶¶¶¶¶¶¶¶¶¶¶Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC ###########Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada §§§§§§§§§§§Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Doha, Qatar ‡‡‡‡‡‡‡‡Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center §§§§§§§§Warren Alpert Medical School of Brown University, Providence ¶¶¶¶¶National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA †††Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Departments of ‡‡‡Pathology, Microbiology and Immunology ########Department of Medicine, Vanderbilt University Medical Centre *********Vanderbilt Ingram Cancer Center, Nashville §§§§§§§§§Department of Pathology, Yale University School of Medicine, New Haven ∥∥∥∥∥∥∥∥∥∥∥Department of Oncology, Montefiore Medical Centre, Albert Einstein College of Medicine ∥∥∥∥∥∥∥Montefiore Medical Center ¶¶¶¶¶¶¶The Albert Einstein College of Medicine, Bronx, NY ********Department of Pathology, Brigham and Women's Hospital #####Cancer Research Institute and Department of Pathology, Beth Israel Deaconess Cancer Center ******Harvard Medical School ¶¶¶¶¶¶¶¶¶¶¶¶Division of Hematology-Oncology, Beth Israel Deaconess Medical Center ††††††††Department of Cancer Biology ‡‡‡‡‡‡‡‡‡‡‡‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO ‡‡‡‡‡Department of Cancer Biology, Mayo Clinic, Jacksonville, FL ∥∥∥∥∥∥Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN ¶¶¶¶¶¶Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA ††††††††††††Department of Pathology, New York University Langone Medical Centre ############New York University Medical School *************Perlmutter Cancer Center §§§§§§§§§§§§§Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University ***************Department of Pathology, Memorial Sloan-Kettering Cancer Center ####Departments of Radiation Oncology and Pathology, Weill Cornell Medicine, New York, NY *****Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX ∥∥∥∥∥∥∥∥∥∥∥∥Pathology Department, Stanford University Medical Centre, Stanford ∥∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Pathology, Stanford University, Palo Alto ***Department of Pathology, School of Medicine, University of California, San Diego §§§§§§§§§§§§§§Research Pathology, Genentech Inc., South San Francisco, CA *************Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda ¶¶¶¶¶¶¶¶¶¶¶¶¶¶Translational Sciences, MedImmune, Gaithersberg, MD §§§§§§Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover ##############Translational Medicine, Merck & Co. Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564448PMC
September 2017

Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC).

Breast 2017 Aug 28;34 Suppl 1:S27-S30. Epub 2017 Jun 28.

Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Melbourne, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776173049
Publisher Site
http://dx.doi.org/10.1016/j.breast.2017.06.023DOI Listing
August 2017

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.

Lancet Oncol 2017 08 7;18(8):1009-1021. Epub 2017 Jul 7.

Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK; Department of Medical Oncology, University College London Hospitals, London, UK. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045173051
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(17)30516-8DOI Listing
August 2017

Advancing Immunotherapy in Metastatic Breast Cancer.

Curr Treat Options Oncol 2017 06;18(6):35

Division of Research, Peter MacCallum Cancer Centre, University of Melbourne, 305 Grattan St, Melbourne, Victoria, 3000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-017-0478-9DOI Listing
June 2017

Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.

Pathology 2017 Feb 31;49(2):141-155. Epub 2016 Dec 31.

Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Vic, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2016.10.010DOI Listing
February 2017

Mouse Models of Tumor Immunotherapy.

Adv Immunol 2016 19;130:1-24. Epub 2016 Jan 19.

QIMR Berghofer Medical Research Institute, Herston, QLD, Australia; University of Queensland, Herston, QLD, Australia; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; University of Melbourne, Parkville, VIC, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.ai.2015.12.004DOI Listing
October 2016

The genomic landscape of breast cancer and its interaction with host immunity.

Breast 2016 Oct;29:241-50

Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2016.07.015DOI Listing
October 2016

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

J Clin Oncol 2016 09 6;34(25):2961-8. Epub 2016 Jun 6.

Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.3061DOI Listing
September 2016

Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis.

Cancer Res 2016 08 24;76(15):4372-82. Epub 2016 May 24.

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. School of Medicine, The University of Queensland, Herston, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-16-0544DOI Listing
August 2016

The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling.

Cancer Res 2016 07 26;76(14):4236-48. Epub 2016 May 26.

Research Division, Peter MacCallum Cancer Centre, East Melbourne, Australia. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia. Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-1553DOI Listing
July 2016

Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Nat Rev Clin Oncol 2016 Apr 15;13(4):228-41. Epub 2015 Dec 15.

Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, East Melbourne, Victoria 8006, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.215DOI Listing
April 2016

Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.

J Clin Oncol 2016 Mar 25;34(9):936-44. Epub 2016 Jan 25.

Chee Khoon Lee, Lucy Davies, Val J. Gebski, Sarah J. Lord, Ian Marschner, and John Simes, University of Sydney; Sarah J. Lord, University of Notre Dame; Ian Marschner, Macquarie University; Paul de Souza, University of Western Sydney, Sydney, New South Wales; Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Angelo Di Leo, Hospital of Prato, Istituto Toscano Tumori, Italy; Stephen Johnston, Royal Marsden Hospital, London; David Cameron, University of Edinburgh, Edinburgh, United Kingdom; Charles Geyer Jr, Virginia Commonwealth University Massey Cancer Center, Richmond, VA; Michael F. Press, University of Southern California, Los Angeles, CA; and Catherine Ellis, GlaxoSmithKline, Collegeville, PA.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/01/21/JCO.2015.62
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.62.4767
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.4767DOI Listing
March 2016

Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Can We Understand It Better?

J Clin Oncol 2016 Feb 11;34(6):521-3. Epub 2016 Jan 11.

Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.7495DOI Listing
February 2016

Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.

Cancer Res 2016 Jan 7;76(2):264-74. Epub 2016 Jan 7.

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. School of Medicine, University of Queensland, Herston, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-1567DOI Listing
January 2016

Molecular segmentation of luminal breast: Reality in 2015?

Breast 2015 Nov 5;24 Suppl 2:S41-3. Epub 2015 Aug 5.

Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.07.010DOI Listing
November 2015

CD73: A potential biomarker for anti-PD-1 therapy.

Oncoimmunology 2015 Nov 5;4(11):e1046675. Epub 2015 May 5.

Cancer Immunology Program; Peter MacCallum Cancer Centre ; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; The University of Melbourne ; Parkville, Australia ; Department of Immunology; Monash University ; Clayton, Australia ; Department of Pathology; University of Melbourne ; Parkville, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1046675DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589050PMC
November 2015

Relevance of tumor-infiltrating lymphocytes in breast cancer.

BMC Med 2015 Aug 24;13:202. Epub 2015 Aug 24.

Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12916-015-0431-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547422PMC
August 2015